Oppenheimer analyst Jay Olson maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $380.00. The company’s ...

Published in Nature Communications, a new study led by the University of Minnesota Medical School and Duke University found that a DNA sequencing test for advanced prostate cancer patients can ...

The feud between Arcellx and Legend Biotech over their anti-BCMA CAR-T therapies for multiple myeloma is getting extra spicy ...

The board of Amgen boosted its quarter dividend by almost 6%. The Thousand Oaks, Calif.-based biotechnology company said Tuesday that it raised its dividend to $2.38 per share for the first quarter, ...

Amgen (NASDAQ:AMGN) declares $2.38/share quarterly dividend, 5.8% increase from prior dividend of $2.25. Forward yield 3.45% ...

Cardiff Oncology’s investigational PLK1 inhibitor paired with standard-of-care treatment showed a 64% overall response rate ...

Biotech companies are making monumental strides in cancer treatment, leveraging cutting-edge technologies to redefine the ...

Latest update on the Dow Jones Industrial Average (DJIA), which recently closed at 44,401.93. Discover market trends, top-performing stocks..

Analysts have recently evaluated Amgen and provided 12-month price targets. The average target is $340.38, accompanied by a high estimate of $405.00 and a low estimate of $215.00. This upward trend is ...

BofA analyst Tim Anderson reinstated coverage of Amgen (AMGN) with an Underperform rating and $256 price target The obesity premium is coming ...

A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key ...

YESINKTEK is the sixth ustekinumab biosimilar approved by the FDA, behind Amgen’s WEZLANA (ustekinumab-auub), approved in Oct. 2023; Alvotech’s SELARSDI (ustekinumab-aekn), approved in April 2024; ...